At the present time, adequate data do not exist to define the proper role of BNP and NT-proBNP in stratifying patients to more aggressive interventional therapy, and the clinician must consider plasma levels of these peptides in the context of other biomarkers and clinical factors before assigning a patient to a proper level of care. More research is needed to identify appropriate pharmacological and interventional strategies for high-risk patients with ACS and elevated levels of BNP or NT-proBNP. In the meantime, we propose the algorithm in Fig. 7 for patients with ACS. Patients who present with ACS and have elevated cardiac troponin or who are in a high TIMI risk category have been shown to benefit from an early interventional approach. In patients with a low TIMI risk score who have a normal troponin result, aggressive intervention may be considered for those patients who have BNP levels >80 pg/mL (cut point based on studies using the Biosite and Bayer assays). Otherwise, a conservative approach may be pursued, with noninvasive testing. Regardless ofwhich ofthese approaches is taken, medical therapy with aspirin, angioten-sin-converting enzyme inhibitors, aldosterone antagonists, ^-blockers, and statins should
Was this article helpful?
Discover secrets, myths, truths, lies and strategies for dealing effectively with cholesterol, now and forever! Uncover techniques, remedies and alternative for lowering your cholesterol quickly and significantly in just ONE MONTH! Find insights into the screenings, meanings and numbers involved in lowering cholesterol and the implications, consideration it has for your lifestyle and future!